Fortschritte bei der Personalisierung der Systemtherapie hepatobiliärer Tumoren
- 26 April 2021
- journal article
- Published by Springer Science and Business Media LLC in Gastro-News
- Vol. 8 (2), 46-53
- https://doi.org/10.1007/s15036-021-2311-3
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.Journal of Clinical Oncology, 2019
- Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.Journal of Clinical Oncology, 2017
- Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.Journal of Clinical Oncology, 2017
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)Nature Reviews Gastroenterology & Hepatology, 2016
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trialBMC Cancer, 2015
- The Diagnosis and Treatment of CholangiocarcinomaDeutsches Ärzteblatt international, 2014
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trialsAnnals of Oncology, 2013
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerThe New England Journal of Medicine, 2010
- LIVER TRANSPLANTATION FOR CHOLANGIOCARCINOMA: RESULTS IN 207 PATIENTS1Transplantation, 2000